Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Benkert

Showing results (11-20 of 135) with videos related to

Pageof 14
Sort By:
Nature Protocols|January 10, 2009
Protein structure homology modeling using SWISS-MODEL workspaceLorenza Bordoli, Florian Kiefer, Konstantin Arnold, et al.
Journal of Sleep Research|February 14, 2024
Effects of obstructive sleep apnea treatment on neurodegenerative biomarker neurofilament light chain and cognitive performanceTony Sehr, Katja Akgün, Pascal Benkert, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|May 26, 2023
Serum Neurofilament light chain (NfL) levels in children with and without neurologic diseasesTobias Geis, Svena Gutzeit, Sotiris Fouzas, et al.
Frontiers in Neuroscience|January 3, 2022
Serum Neurofilament Light Chain: A Marker of Nervous System Damage in MyopathiesAnnika Saak, Pascal Benkert, Katja Akgün, et al.
Scientific Reports|September 23, 2022
Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parametersMarco Hermesdorf, David Leppert, Aleksandra Maceski, et al.
Journal of Neurology|September 25, 2020
Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosisJohannes Lorscheider, Pascal Benkert, Carmen Lienert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2018
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosisJohannes Lorscheider, Pascal Benkert, Carmen Lienert, et al.
Geroscience|June 7, 2023
Serum neurofilament light and white matter characteristics in the general population: a longitudinal analysisMarco Hermesdorf, Niklas Wulms, Aleksandra Maceski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2013
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumorsDamian Wild, Jamshed B Bomanji, Pascal Benkert, et al.
Frontiers in Neuroscience|April 24, 2026
Sex differences in the development, treatment, and prognosis of multiple sclerosis in SwitzerlandTimea-Chiara Annovazzi, Jens Kuhle, Pascal Benkert, et al.
Pageof 14

Showing results (11-20 of 135) with videos related to

Sort By:
Pageof 14
Nature Protocols|January 10, 2009
Protein structure homology modeling using SWISS-MODEL workspaceLorenza Bordoli, Florian Kiefer, Konstantin Arnold, et al.
Journal of Sleep Research|February 14, 2024
Effects of obstructive sleep apnea treatment on neurodegenerative biomarker neurofilament light chain and cognitive performanceTony Sehr, Katja Akgün, Pascal Benkert, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|May 26, 2023
Serum Neurofilament light chain (NfL) levels in children with and without neurologic diseasesTobias Geis, Svena Gutzeit, Sotiris Fouzas, et al.
Frontiers in Neuroscience|January 3, 2022
Serum Neurofilament Light Chain: A Marker of Nervous System Damage in MyopathiesAnnika Saak, Pascal Benkert, Katja Akgün, et al.
Scientific Reports|September 23, 2022
Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parametersMarco Hermesdorf, David Leppert, Aleksandra Maceski, et al.
Journal of Neurology|September 25, 2020
Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosisJohannes Lorscheider, Pascal Benkert, Carmen Lienert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2018
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosisJohannes Lorscheider, Pascal Benkert, Carmen Lienert, et al.
Geroscience|June 7, 2023
Serum neurofilament light and white matter characteristics in the general population: a longitudinal analysisMarco Hermesdorf, Niklas Wulms, Aleksandra Maceski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2013
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumorsDamian Wild, Jamshed B Bomanji, Pascal Benkert, et al.
Frontiers in Neuroscience|April 24, 2026
Sex differences in the development, treatment, and prognosis of multiple sclerosis in SwitzerlandTimea-Chiara Annovazzi, Jens Kuhle, Pascal Benkert, et al.
Pageof 14